Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Accelerating Parkinson’s drug development: The International Linked Clinical Trials initiative
In 2012, Cure Parkinson’s joined forces with Van Andel Institute (VAI) to hold the first international Linked Clinical Trials (iLCT) meeting in Grand Rapids, Michigan. The Committee has since met annually to evaluate and prioritise drugs for clinical trial in Parkinson’s, a review of which has now been published in the Journal of Parkinson’s Disease.
Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the…
Upcoming GBA1 conference in Montreal
Cure Parkinson’s is co-sponsoring a large three-day international conference on June 27th – 29th that will be focused on all aspects of GBA1 research, from basic science to clinical trials.
Time to ROCK-PD
Researchers in Germany are conducting a new phase 2 clinical trial to determine if an existing cardiovascular drug called fasudil, could help people with Parkinson’s.
International Women’s Day and Parkinson’s
On 8 March, we celebrate International Women’s Day by shining a light on the work of female researchers and scientists who have made significant contributions to the Parkinson’s community, and the impact of their work in advancing our understanding of the role of sex and…